We also found that incretin secretion, the target of DPP-4 inhibitors, was maintained in patients with DM1, and treatment with DPP-4 inhibitors reduced glucose levels and increased insulin secretion in some patients. The gene discussed is GCG; the disease is myotonic dystrophy type 1.